Patents by Inventor Robert J. Hariri

Robert J. Hariri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160287635
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: November 16, 2015
    Publication date: October 6, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20160289634
    Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
    Type: Application
    Filed: June 9, 2016
    Publication date: October 6, 2016
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20160279171
    Abstract: Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 29, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20160235790
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Application
    Filed: October 2, 2014
    Publication date: August 18, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Jodi P. GURNEY, Xiaokui ZHANG, Stacy HERB, Robert J. HARIRI
  • Patent number: 9387283
    Abstract: A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: July 12, 2016
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20160166618
    Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent amnion-derived cells (AMDACs). Because mammalian placentas are plentiful and are normally discarded as medical waste, they represent a unique source of medically-useful stem cells.
    Type: Application
    Filed: October 18, 2013
    Publication date: June 16, 2016
    Applicant: ANTHROGENESIS CORPROATION
    Inventors: Uri Herzberg, Robert J. Hariri, Jodi P Gurney
  • Patent number: 9339520
    Abstract: Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: May 17, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Kristen S. Labazzo, Marian Pereira, Sascha Dawn Abramson
  • Publication number: 20160106784
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 21, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
  • Patent number: 9254302
    Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: February 9, 2016
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
  • Publication number: 20150366910
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Xiaokui ZHANG, Robert J. HARIRI, Vanessa VOSKINARIAN-BERSE, Lin KANG, Eric LAW, Stewart ABBOT
  • Patent number: 9216200
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20150313948
    Abstract: Provided herein are uses of compositions comprising extracellular matrix (ECM) and compositions comprising ECM components in the treatment of non-dental oral lesions.
    Type: Application
    Filed: December 6, 2013
    Publication date: November 5, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Jodi P. Gurney, Mohit B. Bhatia, Wolfgang Hofgartner
  • Publication number: 20150313947
    Abstract: Provided herein are methods of treatment of individuals having schizophrenia, or schizophreniform disorder, using angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of and compositions comprising, such cells. A need exists for therapies that can ameliorate or palliate schizophrenia, or a schizophreniform disorder, or symptoms of the same. Provided herein are methods of treating individuals who have schizophrenia, or schizophreniform disorder, comprising administration of therapeutically-effective amounts (numbers) of AMDACs.
    Type: Application
    Filed: December 2, 2013
    Publication date: November 5, 2015
    Inventors: Robert J. Hariri, Jodi P. Gurney
  • Publication number: 20150306150
    Abstract: Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.
    Type: Application
    Filed: July 6, 2015
    Publication date: October 29, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Shmuel Yaccoby, Sascha Abramson, Robert J. Hariri
  • Publication number: 20150283184
    Abstract: The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
    Type: Application
    Filed: June 17, 2015
    Publication date: October 8, 2015
    Applicant: Anthrogenesis Corporation
    Inventor: Robert J. HARIRI
  • Patent number: 9149569
    Abstract: The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: October 6, 2015
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20150267170
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 24, 2015
    Inventor: Robert J. Hariri
  • Patent number: 9139813
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: September 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventor: Robert J. Hariri
  • Publication number: 20150246072
    Abstract: Provided herein are methods for forming three-dimensional tissues in vivo. In one embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells. In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells and at least one composition that comprises an extracellular matrix (ECM). In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells, at least one composition that comprises an extracellular matrix (ECM), and at least one other additional components.
    Type: Application
    Filed: September 3, 2013
    Publication date: September 3, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Mohit B. Bhatia, Robert J. Hariri, Wolfgang Hofgartner, Jia-Lun Wang, Qian Ye
  • Patent number: 9121007
    Abstract: Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: September 1, 2015
    Assignee: ANTHROGENESIS CORPORATIN
    Inventors: Xiaokui Zhang, Shmuel Yaccoby, Sascha Abramson, Robert J. Hariri